PROGRAMME
EHMSG Workshop
Friday, September 11, 2026
08.25 – 08.30 hrs
Welcome by EHMSG President Mirjana Rajilić-Stojanović, Belgrade, Serbia
08.30 – 10.20 hrs Session 01 – Microbiota & Metabolic Syndrome
08.30 – 08.50 hrs
01.01. Gut microbiota and metabolic disorders: pathophysiological insights
Herbert Tilg, Innsbruck, Austria
08.50 – 09.10 hrs
01.02. Helicobacter pylori and Metabolic Syndrome
Francesco Franceschi, Rome, Italy
09.10 – 09.30 hrs
01.03. Gut Microbiota Metabolism and Metabolic Diseases
Katharina Beck, Gothenburg, Sweden
09.30 – 09.50 hrs
01.04. Approved Therapies for Metabolic Syndrome Management
tbc
09.50 – 10.05 hrs
01.05. Talk from Submitted Abstracts
10.05 – 10.20 hrs
01.06. Talk from Submitted Abstracts
10.20 – 11.00 hrs | Coffee Break
11.00 – 12.25 hrs Session 02 – Therapeutic Microbiota Modulation and New Regulation of FMT (Parallel Session)
11.00 – 11.20 hrs
02.01. Update on the regulatory aspects of FMT
Simon Mark Baunwall, Aarhus, Denmark
11.20 – 11.40 hrs
02.02. How to build a FMT centre: the Eastern Europe experience
Georgiana-Emmanuela Gilca-Blanariu, Iasi, Romania
11.40 – 11.55 hrs
02.03. Microbiome-targeted therapy improves symptoms in Rett syndrome
Francesco Strati, Kaunas, Lithuania
11.55 – 12.10 hrs
02.04. Achillea millefolium exerts distinct modulatory effects on gut bacterial and fungal communities in the TIM-2 in vitro model of the colon
Ana Bacis, Belgrade, Serbia
12.10 – 12.25 hrs
02.05. Paromomycin is an effective treatment for Enterobacteriaceae overgrowth and related gastrointestinal symptoms: a retrospective analysis
Ernesto Margarita, Rome, Italy
11.00 – 12.25 hrs | Session 03 – AI and omics in Helicobacter pylori (Parallel Session)
11.00 – 11.20 hrs
03.01. Can AI be the Pathologist Friend? / How can Pathologists take advantage of AI?
Ari Ristimäki, Helsinki, Finland
11.20 – 11.40 hrs
03.02. AI in Endoscopy
Yoshio Yamaoka, Yufu, Japan
11.40 – 11.55 hrs
03.03. Assessing the accuracy of commonly used bioinformatic tools to predict antibiotic resistance phenotypes from Helicobacter pylori genomes
Farah Mahmud, Nottingham, United Kingdom
11.55 – 12.10 hrs
03.04. Epigenomic Landscape of Helicobacter pylori: Direct Detection and Validation of DNA Methylation in the Helicobacter pylori Genome Project
Constanza Camargo, Rockville, MD, United States
12.10 – 12.25 hrs
03.05. Identification of Plasma Exosomal miRNA Signatures as Non-invasive Biomarkers for Gastric Dysplasia and Early Gastric Cancer
Gwang Ha Kim, Busan, Korea
12.25 – 14.00 hrs | Lunch Break & Poster Viewing
14.00 – 15.00 hrs Session 04 – Industry-Sponsored Satellite Symposium
15.00 – 16.25 hrs Session 05 – New Targets for Clinical Applications in FMT and microbiome modulation (Parallel Session)
15.00 – 15.20 hrs
05.01. FMT in oncology
Gianluca Ianiro, Rome, Italy
15.20 – 15.40 hrs
05.02. FMT in noncommunicable disorders
Nicolas Benech, Lyon, France
15.40 – 15.55 hrs
05.03. Feasibility and Symptom Improvement Signals of Oral Capsule Versus Colonoscopic Fecal Microbiota Transplantation for Irritable Bowel Syndrome: A Double-Blind Randomized Trial (CAP-COLONO Study)
Ratha-korn Vilaichone, Pathumthani, Thailand
15.55 – 16.10 hrs
05.04. Modulation of the Gut Microbiota by a gluten-free diet in healthy individuals
Lisa Lungaro, Palermo/Ferrara, Italy
16.10 – 16.25 hrs
05.05. Antibiotic Pre-conditioning for fecal microbiota transplantation does not impair gut barrier integrity in mice
Aurora Sveva Carlà, Rome, Italy
15.00 – 16.30 hrs Session 06 – Helicobacter pylori Screening (Parallel Session)
15.00 – 15.20 hrs
06.01. Risk of Gastric Adenocarcinoma after Eradication of Helicobacter pylori
Markus Gerhard, Munich, Germany
15.20 – 15.40 hrs
06.02. New EU Gastric Cancer Prevention Guidelines
Marcis Leja, Riga, Latvia
15.40 – 16.00 hrs
06.03. Korean Registry on the Current Management of Helicobacter pylori (K-Hp-Reg)
Joon Sung Kim, Seoul, Korea
16.00 – 16.15 hrs
06.04. Helicobacter pylori eradication and local recurrence after endoscopic treatment of gastric low-grade dysplasia: a Korean multicenter cohort study
Jong Yeul Lee, Goyang, Korea
16.15 – 16.30 hrs
06.05. Helicobacter pylori Screen and treat study for the primary prevention of gastric cancer in young adults in six EU member states—TOGAS Project
Bojan Tepes, Ljubljana, Slovenia
16.30 – 17.00 hrs | Coffee Break
17.00 – 18.40 hrs Session 07 – Antimicriobial Resistance in Helicobacter pylori and Microbiota
17.00 – 17.20 hrs
07.01. The impact of travelling on resistome
John Penders, Maastricht, Netherlands
17.20 – 17.40 hrs
07.02. Antimicrobial Treatment and Resistome
Ioanna Chatzigiannidou, Lyngby, Denmark
17.40 – 18.00 hrs
07.03. The optimization of helicobacter eradication therapy based on the results of KCAST-HP
Ji Jong Ahn, Seoul, Korea
18.00 – 18.20 hrs
07.04. Challenges for Helicobacter pylori Resistance
Christian Schulz, Munich, Germany
18.20 – 18.40 hrs
07.05. Helicobacter pylori Resistance in Patients with Therapeutic Failure – Results from Tertiary Center in Serbia
Dragana Mijač, Belgrade, Serbia
20.00 hrs | Conference Dinner
Saturday, September 12, 2026
08.30 - 09.50 hrs Session 08 - Oncobiome
08.30 – 08.50 hrs
08.01. Microbiome in Immune Checkpoint Inhibition
Johannes Björk, Groningen, Netherlands
08.50 – 09.10 hrs
08.02. Microbiome Immune Interactions in Cancer
Luigi Nezi, Milan, Italy
09.10 – 09.30 hrs
08.03. Intra-Tumoral Microbiome
Emilie Bessède, Bordeaux, France
09.30 – 09.50 hrs
08.04. The gastric microbiome in gastric carcinogenesis and the emerging role of Streptococcus anginosus
Céu Figueiredo, Porto, Portugal
09.50 – 10.20 hrs | Coffee Break
10.20 – 11.45 hrs Session 09 – Microbiome as a Biomarker (Parallel Session)
10.20 – 10.40 hrs
09.01. Evaluating Microbial Dysbiosis through Meta-Analysis
Georgina Hold, Sydney, Australia
10.40 – 11.00 hrs
09.02. Microbiome Testing in Clinical Practice
Juozas Kupcinskas, Kaunas, Lithuania
11.00 – 11.15 hrs
09.03. Characterization of gut bacterial and fungal community in paediatric progressive familial Intrahepatic cholestasis
Konrad Lehr, Magdeburg, Germany
11.15 – 11.30 hrs
09.04. Gut microbiome predicts risk of aggressive disease course in ulcerative colitis: Development and validation of a risk classifier
Cristina Casén, Oslo, Norway
11.30 – 11.45 hrs
09.05. Gastric microbiota profiles in autoimmune gastritis compared to H. pylori gastritis: a multicenter prospective cross‑sectional study
Ricardo Vassapoli, Munich, Germany
10.20 -11.45 hrs Session 10 – Unfinished Agenda for Helicobacter pylori (Parallel Session)
10.20 – 10.40 hrs
10.01. Optimizing Current Helicobacter pylori Therapies: Strategies to Improve Efficacy in Clinical Practice
Theodore Rokkas, Athens, Greece
10.40 – 11.00 hrs
10.02. Helicobacter pylori Search-and-Treat Policy: Current Challenges
Colm O’Morain, Dublin, Ireland
11.00 – 11.15 hrs
10.03. Is bismuth-containing therapy still effective and safe in patients infected by helicobacter pylori? A six-years multicentre real life study
Francesco Di Mario, Parma, Italy
11.15 – 11.30 hrs
10.04. Long-Term Impact of Helicobacter Pylori Eradication on Splenectomy Outcomes in Refractory Idiopathic Thrombocytopenic Purpura: A 10-Year Follow-Up Study
Khalighi Amir, San Diego, CA, United States
11.30 – 11.45 hrs
10.05. Experience with Rifabutin-Containing Therapy in 900 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain
11.45 – 13.30 hrs | Lunch Break & Poster Viewing
13.30 – 14.55 hrs Session 11 – Probiotics (Parallel Session)
13.30 – 13.50 hrs
11.01. Next Generation Probiotics and Aging
Miroslav Dinić, Belgrade, Serbia
13.50 – 14.10 hrs
11.02. Psychobiotics
Gerard Clarke, Cork, Ireland
14.10 – 14.25 hrs
11.03. Effect of Saccharomyces boulardii supplementation during proton pump inhibitor therapy on gut microbiome and symptom outcomes in reflux disease: a prospective multicenter study
Hyo-Joon Yang, Seoul, Korea
14.25 – 14.40 hrs
11.04. Efficacy of Bifidobacterium longum BBH-016 on Gastrointestinal Symptoms and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial
Ho-Kyoung Lee, Seoul, Korea
14.40 – 14.55 hrs
11.05. From Bench to Bedside: A 10-Year Translational Journey to Develop Antimicrobial-Tolerant Probiotics to Reduce Adverse Events During Helicobacter pylori Eradication Treatment: Results of a Randomised Double-Blind Placebo-Controlled Trial
Giulia Fiorini, Bologna, Italy
13.30 – 14.55 hrs | Session 12 – Gastric Cancer and Helicobacter pylori (Parallel Session)
13.30 – 13.50 hrs
12.01. Mucosal Immunity and Helicobacter Pylori
Raquel Mejias-Luque, Munich, Germany
13.50 – 14.10 hrs
12.02. The Role of the Tumor Microenvironment in Gastric Carcinogenesis
Martijn Gloerich, Utrecht, Netherlands
14.10 – 14.25 hrs
12.03. Non-Helicobacter pylori Helicobacter is associated with inflammation and cellular stress in patients with functional dyspepsia
Jona Verstraelen, Antwerp, Belgium
14.25 – 14.40 hrs
12.04. Temporal Trend of Gastric Cancer Burden Attributed to Helicobacter pylori in the World
Wai Keung Leung, Hong Kong, China
14.40 – 14.55 hrs
12.05. Hydrogen sulfide donors suppress Helicobacter pylori-driven pro-carcinogenic stromal reprogramming and potentiate metronidazole
Gracjana Krzysiek-Maczka, Krakow, Poland
14.55 – 15.30 hrs | Coffee Break
15.30 – 16.30 hrs Session 13 – Progress in the clinical management of H.pylori infection - Maastricht 1996 - 2026
15.30 – 15.50 hrs
13.01. Diagnostics
Francis Mégraud, Bordeaux, France
15.50 – 16.10 hrs
13.02. Therapeutics
Colm O’Morain, Dublin, Ireland
16.10 – 16.30 hrs
13.03. Clinical Strategies
Peter Malfertheiner, Munich, Germany
16.30 – 18.00 hrs Session 14 – Closing Session
16.30 – 16.55 hrs
14.01. Awarding of the Marshall and Warren Medal 2026 to Tomica Milosavljevic, Belgrade, Serbia
16.30 – 16.40 hrs
Introduction by Peter Malfertheiner, Munich, Germany
16.40 – 16.55 hrs
Short talk Tomica Milosavljevic, Belgrade, Serbia
16.55 – 17.15 hrs
14.02. Awarding of the EHMSG Oral and Poster Awards
Poster Jury:
-
Gianluca Ianiro, Rome, Italy
-
Christian Schulz, Munich, Germany
-
Sinéad Smith, Dublin, Ireland
17.15 – 17.30 hrs
14.03. Presentation of the EHMSG Journal
Francesco Franceschi, Rome, Italy
17.30 – 17.45 hrs
14.04. Presentation of the next meeting in Athens
Theodore Rokkas, Athens, Greece
17.45 – 18.00 hrs
Closing Remarks